In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
Bayer wins FDA Priority Review for Kerendia label expansion in CKD tied to type I diabetes after strong phase III data.
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Bayer Aktiengesellschaft (BAYRY) and Roche Holding AG (RHHBY). But which of these two companies is the best option for those looking for undervalued stocks?
| Health Care Equipment & Supplies Industry | Healthcare Sector | William N. Anderson CEO | XSTU Exchange | US0727303028 ISIN |
| DE Country | 90,587 Employees | 28 Apr 2026 Last Dividend | 20 Sep 2017 Last Split | - IPO Date |
Bayer Aktiengesellschaft is a globally recognized life science company that operates worldwide with a vast array of subsidiaries. Established in 1863 and with its headquarters located in Leverkusen, Germany, the company engages in extensive research, development, and marketing activities across three major segments: Pharmaceuticals, Consumer Health, and Crop Science. Bayer's mission is to address some of the most pressing global challenges by providing innovative solutions in healthcare and agriculture. The company has fostered numerous collaborations with leading entities such as Acuitas Therapeutics, Inc., Peking University, the Swiss Tropical and Public Health Institute, bit.bio Ltd., Hologic, Inc., Twist Bioscience Corporation, and CrossBay Medical Inc., among others. These partnerships mainly focus on advancing Bayer's research initiatives in gene editing, pharmaceutical research, the development of therapeutics, and improving diagnostic solutions for diseases like breast cancer. Additionally, Bayer teams up with Thermo Fisher Scientific, further enhancing its product distribution capabilities which span wholesalers, pharmacies, supermarket chains, online retailers, hospitals, and direct sales to farmers.
This division primarily focuses on the development and sale of prescription medications in cardiology and women’s health care. It also encompasses specialty therapeutics in oncology, hematology, ophthalmology, and the burgeoning fields of cell and gene therapy. Moreover, Bayer is involved in the provision of diagnostic imaging equipment and solutions, along with contrast agents, catering to the healthcare industry's needs for precise and early disease detection.
Under this segment, Bayer markets a wide array of non-prescription, over-the-counter medicines designed for self-medication and self-care. The products span various categories including nutritional supplements, allergy relief, cough and cold remedies, dermatology, pain management, cardiovascular risk prevention, and digestive health. This segment illustrates Bayer's commitment to supporting everyday health and wellness through accessible healthcare solutions.
This sector of Bayer’s operations is dedicated to the agricultural industry, focusing on the breeding, propagation, and production/processing of seeds. Offerings also include seed dressing technologies aimed at improving crop yields and resilience. By integrating scientific advancements into agriculture, Bayer seeks to address food security and sustainability challenges, reinforcing its role in supporting the agricultural community.